Trial Profile
An open-label extension study of rufinamide given as adjunctive therapy in patients with refractory partial seizures.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Rufinamide (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 13 Nov 2019 Status changed from completed to discontinued.
- 11 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Aug 2009 Planned initiation date (Jan 2011) added as reported by ClinicalTrials.gov.